In December 2024, we received approval to initiate our Phase 1b clinical trial of GT-02287 in people with GBA1 or idiopathic ...

Gain Therapeutics, Inc. (Nasdaq: GANX) ("Gain", or the "Company"), a clinical-stage biotechnology company leading the discovery and development of the ...

Gain Therapeutics (GANX) provided a letter to shareholders from the Company’s President and CEO, Gene Mack, which read in part,”With 2025 ...

Researchers examined 72 participants with a condition known as idiopathic Rapid Eye Movement Behavior Disorder (iRBD), a behavioral disorder that has been linked to Parkinson’s disease.

Idiopathic Parkinson’s disease (IPD) is a central nervous system disorder affecting the basal ganglia that is caused by death of dopamine-producing cells in the substantia nigra. Although IPD is ...

Kenai Therapeutics, a biotechnology company leveraging induced pluripotent stem cell (iPSC) technology to discover and ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

AD: Autonomic dysfunction; DaT: Dopamine transporter; MIBG: Metaiodobenzylguanidine; PD: Parkinson's disease ... to diagnose a clinically possible idiopathic PD. A clinically probable PD might ...

Idiopathic normal pressure hydrocephalus ... vestibular diseases and Parkinson's disease. The differentiation between INPH and Parkinson's disease can be challenging. Both diseases share a ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.